Although both short and long-term administration of thiazolidinedione (TZD) and PPARγ agonists, Rosiglitazone, have been demonstrated to alleviate HS in patients with NASH(Stefanovic-Racic et al. 2008; Ratziu et al. 2008, 2010). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.